A French-Swiss research team is developing a smart bra for detecting breast cancer more accessible than through mammography.
The European Council, the European Parliament, and the outgoing European Commission have agreed upon the priorities and structure of Horizon Europe (2021 to 2027), the next seven-year research and innovation programme of the European Union. This autumn, they will decide on the Parliaments proposal to increase its budget from €100bn to €120bn.
GARDP has called up the global community to develop and deliver five new treatments that break antimicrobial resistance (AMR) by 2025.
Germany-based MorphoSys AG announced that its Supervisory Board has today appointed Jean-Paul Kress, M.D., as its new Chief Executive Officer. The appointment will take effect on September 1, 2019.
Sanifit has bagged €72.2m in Spains largest private biotech fundraise.
Genfit SA has licenced the Greater China commercialisation rights for its NASH drug elafibranor to Terns Pharmaceuticals Inc.
Life sciences venture capitalist Vesalius Biocapital III has announced the final close of the VBC III fund at €120m.
Erytech Pharma has inked a deal with SQZ Biotechnologies Inc. to develop new immune modulating therapies.
Sanofis and Regenerons IL-33 blocker REGN3500 met primary Phase II endpoint in asthma patients.
After the birth of the first genome-edited babies in China, regulators, researchers, and bioethics experts seek ways to ban clinical use of germline editing, in order to protect the innovative field from misuse for human enhancement and side effect-prone application forgene correction and human enhancement.